Pfizer Inc. recently published the findings from two pivotal Phase III studies of crisaborole topical ointment 2 percent, formerly known as AN2728.
The studies can be found in the current issue of the Journal of the American Academy of Dermatology online.
Dr. Amy Paller, Walter J. Hamlin Professor and Chair of Dermatology, Professor of Pediatrics at Northwestern University Feinberg School of Medicine, detailed the treatment outcomes.
“Atopic dermatitis, or eczema, is a chronic, inflammatory skin disease that affects millions of children and adults," she said. "There have been no new therapies approved in the United States for people with atopic dermatitis in the past 15 years. The results seen in these pivotal Phase II studies demonstrate that crisaborole, if approved, could be a meaningful treatment option for patients with mild to moderate atopic dermatitis.”
The comprehensive results of the Phase III studies, known as AD-301 and AD-302, show that crisaborole met both the primary and secondary goals for the treatment of atopic dermatitis (AD) in children ages two and up and for adults compared to vehicle ointment. The adverse events of crisaborole were rare, mild to moderate and comparable to vehicle ointment.